MOLMED is a

biotechnology Biotechnology is the integration of natural sciences and engineering sciences in order to achieve the application of organisms, cells, parts thereof and molecular analogues for products and services. The term ''biotechnology'' was first used b ...

company founded in 1996 in Milan. It originally operated as

contract manufacturing organization A contract manufacturing organization (CMO), more recently referred to (and more commonly used now) as a contract development and manufacturing organization (CDMO) to avoid the acronym confusion of Chief Medical Officer or Clinical Monitoring Organ ...

and other services for companies developing

gene therapy Gene therapy is a medical field which focuses on the genetic modification of cells to produce a therapeutic effect or the treatment of disease by repairing or reconstructing defective genetic material. The first attempt at modifying human D ...

and

cell therapy Cell therapy (also called cellular therapy, cell transplantation, or cytotherapy) is a therapy in which viable cells are injected, grafted or implanted into a patient in order to effectuate a medicinal effect, for example, by transplanting T-c ...

products. In 2000, the company changed its business model and started to develop products of its own. In 2001, it signed an agreement with

San Raffaele Hospital The San Raffaele Hospital (also ''Istituto scientifico universitario San Raffaele'' or ''ospedale San Raffaele'', ''HSR'' or ''OSR'') is a university hospital situated in Segrate, the Province of Milan, Italy Italy ( it, Italia ), officia ...

, that gave MolMed an option to license any gene therapy or cell therapy invention made at the hospital in the fields of cancer and HIV. The company was listed on the Milan Stock Exchange in 2008. In early 2015, MolMed partnered with

GlaxoSmithKline GSK plc, formerly GlaxoSmithKline plc, is a British Multinational corporation, multinational pharmaceutical and biotechnology company with global headquarters in London, England. Established in 2000 by a Mergers and acquisitions, merger of Gl ...

related to GSK's acquisition of

Strimvelis Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, sold under the brand name Strimvelis, is a medication used to treat severe combined immunodeficiency ...

; MolMed had been involved in the early development of the product. In March 2020 Fininvest, the reference shareholder with 23.13%, announced its intention to participate in the total takeover bid of the Japanese Agc (Mitsubishi) at the price of 0.518 euros per share, with a 110% premium compared to the price recorded in the session of the previous day (0.24 euro).

References

{{Reflist, 2

External links

Official website
Companies established in 1996